Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in miceAlexandra Schäfer, Timothy P. Sheahan, Kwon Soo Chun et al.|Science Translational Medicine|2022Cited by 83
Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral AgentRaju Subramanian, Bill J. Smith, Jennifer Tang et al.|Molecular Pharmaceutics|2023Cited by 52
Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in miceAlexandra Schäfer, Timothy P. Sheahan, David R. Martinez et al.|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 24
Selective depletion of HBV-infected hepatocytes by class A capsid assembly modulators requires high levels of intrahepatic HBV core proteinDmytro Kornyeyev, Dara Burdette, Zhijuan Song et al.|Antimicrobial Agents and Chemotherapy|2024Cited by 6
Human pharmacokinetics prediction with an <i>in vitro</i>–<i>in vivo</i> correction factor approach and <i>in vitro</i> drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy<sup>®</sup> for the treatment of HIV-1 infectionRaju Subramanian, Bill J. Smith, Jianhong Wang et al.|Xenobiotica|2022Cited by 5